We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.
- Authors
Criscuolo, Marianna; Trecarichi, Enrico Maria
- Abstract
Patients suffering from hematological malignancies are at high risk for severe infections, including in particular bloodstream infections, which represent one of the most frequent life-threatening complications for these patients, with reported mortality rates reaching 40%. Furthermore, a worrisome increase in antimicrobial resistance of Gram-negative bacteria (e.g., cephalosporin- and/or carbapenem-resistant Enterobacteriaceae and multidrug-resistant (MDR) Pseudomonas aeruginosa) involved in severe infectious complications among patients with hematological malignancies has been reported during the last years. The two novel combination of cephalosporins and β-lactamase inhibitors, ceftolozane/tazobactam and ceftazidime/avibactam, were recently approved for treatment of complicated intra-abdominal and urinary tract infections and nosocomial pneumonia and display activity against several MDR Gram-negative strains. Although not specifically approved for neutropenic and/or cancer patients, these drugs are used in this setting due to increasing rates of infections caused by MDR Gram-negative bacteria. The aim of this review is to describe the actual evidence from scientific literature about the "real-life" use of these two novel drugs in patients with hematological malignancies and infections caused by MDR Gram-negative bacteria.
- Subjects
HEMATOLOGIC malignancies; CARBAPENEM-resistant bacteria; URINARY tract infections; CEFTAZIDIME; TAZOBACTAM; ACINETOBACTER baumannii
- Publication
Antibiotics (2079-6382), 2020, Vol 9, Issue 2, p58
- ISSN
2079-6382
- Publication type
Article
- DOI
10.3390/antibiotics9020058